

EDITORIAL COMMENT

Straining the RV to Predict the Future*



André La Gerche, MD, PhD,^{†‡§} Timothy J. Roberts, MD^{†‡}

It would seem that the “oft forgotten ventricle” can be forgotten no longer. For many decades, we have looked to the left ventricle (LV) as the major determinant of a patient’s cardiac health and prognosis, but a study in this issue of *iJACC* by Park et al. (1) reminds us that the right ventricle (RV) is an important predictor of clinical outcomes and possibly the most important. It is not surprising that RV function is a critical determinant of survival in pathologies of the pulmonary vasculature, such as pulmonary arterial hypertension (2,3). However, RV function is also an important prognostic marker in conditions that have traditionally been regarded as primarily LV pathologies such as congestive heart failure (4-6) and acute myocardial infarction (7-9). Whether measured with echocardiographic M-mode, 2-dimensional (2D), newer strain techniques, or magnetic resonance imaging, the conclusions are concordant; RV function can be reliably assessed and is a critical marker of clinical outcomes even after clinical and LV parameters have been taken into account.

SEE PAGE 161

Why does the RV provide such a useful window for the prediction of cardiac outcomes? As summarized in **Figure 1**, RV function reflects, not only the intrinsic myocardial contractility of the RV, but also the afterload effect imposed by increases in LV filling pressures and pulmonary vascular pathology. As compared with the LV, RV function is more profoundly affected by increases in afterload (10), and therefore, the RV becomes a very sensitive barometer of any “downstream” factors. In the post-myocardial infarction setting, echocardiographic estimates of

pulmonary artery pressures provide important prognostic information (11), most likely as a consequence of raised LV filling pressures. The combination of raised pulmonary pressures and RV dysfunction suggests that the contractile reserve is struggling to maintain output against the heightened afterload and portends a particularly ominous prognosis (2,12). Overall cardiac output is “only as good as the worst ventricle,” and Park et al. (1) provide yet more evidence that the RV can represent a weak link following myocardial infarction. However, a more comprehensive assessment including afterload estimates would have enabled Park et al. to provide greater insights into whether the predominant pathology is contractile impairment of the RV, heightened afterload as a result of LV failure, or a combination of both.

Most previous studies have used simple measures such as RV fractional area change or tricuspid annular plane excursion to demonstrate the prognostic importance of RV function in patients with heart failure or recent myocardial infarction. As an important advance, Park et al. (1) compare these established measures with newer 2D deformation measures and conclude that RV longitudinal strain provides better predictive accuracy. They used velocity vector imaging, a technique that tracks unique 2D ultrasound patterns within the RV endocardium and measures the distance and direction of their movement between image frames. This is similar, but not identical, to other 2D strain techniques, and the degree to which the results of this study can be generalized remains untested (13). Furthermore, deformation of the interventricular septum is predominantly affected by the LV, and there is contention over whether it should be incorporated in global measures of RV function. The data of Park et al. (1) suggest that these unresolved issues may be of limited importance. They demonstrated that all measures of RV function predicted cardiac events, and thus we may conclude that quibbling over which is the best measure should not obscure the importance of measuring the RV with something. However, if all tools are available, then 2D strain represents a


*Editorials published in *iJACC* reflect the views of the authors and do not necessarily represent the views of *iJACC* or the American College of Cardiology.

From the [†]Heart Centre, St Vincent’s Hospital Melbourne, Fitzroy, Australia; [‡]St Vincent’s Department of Medicine, University of Melbourne, Fitzroy, Australia; and the [§]Department of Cardiovascular Medicine, University Hospitals Leuven, Leuven, Belgium. Both authors have reported that they have no relationships relevant to the contents of this paper to disclose.

simple and efficient measure that may provide a better summary of global RV function than traditional measures.

Does the association between RV dysfunction and worse outcomes matter? Can this information be used to improve clinical outcomes? The cynic might argue that there are no specific RV treatments and so these findings are largely academic. However, it is important to note that improvements in LV function and LV loading impact favorably on the RV, both by means of direct ventricular interaction and by the fact that reductions in LV filling pressures will decrease the pulmonary afterload. Thus, RV function may be a marker of treatment efficacy that provides the clinician with a more accurate means of targeting those patients in whom more aggressive therapy may be required. For example, RV measures are not currently considered in patient selection algorithms for defibrillator or synchronization device therapies. There is no evidence to support this practice, but given that RV dysfunction is so clearly associated with worse patient outcomes, it would seem a logical hypothesis to aim more aggressive treatment at these patients. Furthermore, with some evolving optimism that pulmonary vasodilators may have a role to play in the treatment of heart failure (14), successful therapy may be dependent on selecting patients with RV impairment.

There have been massive advances in the past decades in the management of myocardial infarction and heart failure. It may be that further significant



advances are going to require better selection of treatments for specific patients. The study of Park et al. (1) contributes to an exciting evolving field in which we are getting better at quantifying RV dysfunction and identifying at-risk patients. Therapeutic decisions influenced by RV strain measurements may not be so far away.

REPRINT REQUESTS AND CORRESPONDENCE: Dr. André La Gerche, Heart Centre, St Vincent's Hospital, 41 Victoria Parade, Fitzroy 3065, Australia. E-mail: Andre.LaGerche@svhm.org.au.

REFERENCES

1. Park SJ, Park J-H, Lee HS, et al. Impaired RV global longitudinal strain is associated with poor long-term clinical outcomes in patients with acute inferior STEMI. *J Am Coll Cardiol Img* 2015;8:161-9.
2. van de Veerdonk MC, Kind T, Marcus JT, et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. *J Am Coll Cardiol* 2011;58:2511-9.
3. Fine NM, Chen L, Bastiansen PM, et al. Outcome prediction by quantitative right ventricular function assessment in 575 subjects evaluated for pulmonary hypertension. *Circ Cardiovasc Imaging* 2013;6:711-21.
4. Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. *J Am Coll Cardiol* 2001;37:183-8.
5. Gulati A, Ismail TF, Jabbour A, et al. The prevalence and prognostic significance of right ventricular systolic dysfunction in nonischemic dilated cardiomyopathy. *Circulation* 2013;128:1623-33.
6. Motoki H, Borowski AG, Shrestha K, et al. Right ventricular global longitudinal strain provides prognostic value incremental to left ventricular ejection fraction in patients with heart failure. *J Am Soc Echocardiogr* 2014;27:726-32.
7. Antoni ML, Scherp tong RW, Atary JZ, et al. Prognostic value of right ventricular function in patients after acute myocardial infarction treated with primary percutaneous coronary intervention. *Circ Cardiovasc Imaging* 2010;3:264-71.
8. Zornoff LA, Skali H, Pfeffer MA, et al. Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. *J Am Coll Cardiol* 2002;39:1450-5.
9. Verma A, Pfeffer MA, Skali H, et al. Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction. *Am Heart J* 2011;161:1156-62.
10. MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. *Part One. Am J Respir Crit Care Med* 1994;150:833-52.
11. Mutlak D, Lessick J, Carasso S, et al. Utility of pulmonary hypertension for the prediction of heart failure following acute myocardial infarction. *Am J Cardiol* 2012;109:1254-9.
12. Aronson D, Darawsha W, Atamna A, et al. Pulmonary hypertension, right ventricular function, and clinical outcome in acute decompensated heart failure. *J Cardiac Fail* 2013;19:665-71.
13. Marwick TH. Will standardization make strain a standard measurement? *J Am Soc Echocardiogr* 2012;25:1204-6.
14. Cooper TJ, Guazzi M, Al-Mohammad A, et al. Sildenafil in Heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design. *Eur J Heart Fail* 2013;15:119-22.

KEY WORDS acute ST-segment elevation myocardial infarction, right ventricular function, strain echocardiography